Vericel Corp (NASDAQ:VCEL) – Equities research analysts at Piper Jaffray Companies increased their Q4 2019 earnings estimates for Vericel in a note issued to investors on Wednesday, September 5th. Piper Jaffray Companies analyst E. Tenthoff now anticipates that the biotechnology company will post earnings per share of $0.06 for the quarter, up from their previous forecast of $0.04.

Vericel (NASDAQ:VCEL) last released its quarterly earnings results on Monday, August 6th. The biotechnology company reported ($0.12) earnings per share (EPS) for the quarter, hitting the consensus estimate of ($0.12). The business had revenue of $19.01 million during the quarter, compared to the consensus estimate of $18.51 million. Vericel had a negative return on equity of 37.86% and a negative net margin of 23.35%.

Several other research firms also recently issued reports on VCEL. Needham & Company LLC cut their price target on Vericel from $15.00 to $14.00 and set a “buy” rating for the company in a research note on Wednesday, August 8th. BidaskClub downgraded Vericel from a “strong-buy” rating to a “buy” rating in a research note on Friday, June 15th. BTIG Research reaffirmed a “buy” rating and set a $17.00 price target on shares of Vericel in a research note on Tuesday, August 7th. Finally, LADENBURG THALM/SH SH raised Vericel from a “neutral” rating to a “buy” rating in a research note on Monday, July 16th. One analyst has rated the stock with a hold rating, five have issued a buy rating and one has given a strong buy rating to the company’s stock. The company currently has a consensus rating of “Buy” and an average target price of $15.00.

NASDAQ:VCEL opened at $12.75 on Monday. The firm has a market cap of $551.17 million, a PE ratio of -25.40 and a beta of 2.98. The company has a debt-to-equity ratio of 0.16, a current ratio of 7.72 and a quick ratio of 7.48. Vericel has a 52-week low of $3.30 and a 52-week high of $14.75.

A number of hedge funds have recently made changes to their positions in VCEL. Trexquant Investment LP acquired a new position in Vericel in the 1st quarter valued at about $363,000. Northern Trust Corp raised its stake in Vericel by 18.8% in the 1st quarter. Northern Trust Corp now owns 75,528 shares of the biotechnology company’s stock valued at $751,000 after purchasing an additional 11,960 shares during the last quarter. JPMorgan Chase & Co. acquired a new position in Vericel in the 1st quarter valued at about $845,000. PNC Financial Services Group Inc. acquired a new position in Vericel in the 1st quarter valued at about $6,298,000. Finally, Timpani Capital Management LLC acquired a new position in Vericel in the 1st quarter valued at about $2,089,000. 76.47% of the stock is owned by hedge funds and other institutional investors.

In related news, Director Paul K. Wotton sold 30,000 shares of the business’s stock in a transaction dated Monday, June 18th. The shares were sold at an average price of $12.06, for a total value of $361,800.00. Following the completion of the transaction, the director now owns 5,000 shares of the company’s stock, valued at approximately $60,300. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website. Also, Director Steven C. Gilman sold 9,000 shares of the business’s stock in a transaction dated Tuesday, September 4th. The shares were sold at an average price of $12.03, for a total transaction of $108,270.00. Following the completion of the transaction, the director now directly owns 9,000 shares of the company’s stock, valued at approximately $108,270. The disclosure for this sale can be found here. Insiders own 4.70% of the company’s stock.

Vericel Company Profile

Vericel Corporation, a commercial-stage biopharmaceutical company, researches, develops, manufactures, markets, and sells patient-specific expanded cellular therapies to repair and regenerate damaged tissues and organs. It markets autologous cell therapy products, including MACI, an autologous cellularized scaffold product for the repair of symptomatic, and single or multiple full-thickness cartilage defects of the knee; and Carticel, an autologous chondrocyte implant for the repair of symptomatic cartilage defects of the femoral condyle caused by acute or repetitive trauma in patients that have inadequate response to a prior arthroscopic or other surgical repair procedure.

See Also: How do investors use RSI to grade stocks?

Earnings History and Estimates for Vericel (NASDAQ:VCEL)

Receive News & Ratings for Vericel Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Vericel and related companies with MarketBeat.com's FREE daily email newsletter.